CA3240991A1 - Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus - Google Patents
Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus Download PDFInfo
- Publication number
- CA3240991A1 CA3240991A1 CA3240991A CA3240991A CA3240991A1 CA 3240991 A1 CA3240991 A1 CA 3240991A1 CA 3240991 A CA3240991 A CA 3240991A CA 3240991 A CA3240991 A CA 3240991A CA 3240991 A1 CA3240991 A1 CA 3240991A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- gepotidacin
- vancomycin
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263301522P | 2022-01-21 | 2022-01-21 | |
| US63/301,522 | 2022-01-21 | ||
| PCT/EP2023/051177 WO2023139147A1 (en) | 2022-01-21 | 2023-01-19 | Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3240991A1 true CA3240991A1 (en) | 2023-07-27 |
Family
ID=85108785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3240991A Pending CA3240991A1 (en) | 2022-01-21 | 2023-01-19 | Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250099535A1 (https=) |
| EP (1) | EP4465989A1 (https=) |
| JP (1) | JP2025502442A (https=) |
| CN (1) | CN118574619A (https=) |
| CA (1) | CA3240991A1 (https=) |
| WO (1) | WO2023139147A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008240764C1 (en) | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| EP3946342A1 (en) * | 2019-04-03 | 2022-02-09 | GlaxoSmithKline Intellectual Property Development Limited | Gepotidacin for use in the treatment of bacterial urinary tract infections |
-
2023
- 2023-01-19 JP JP2024543244A patent/JP2025502442A/ja active Pending
- 2023-01-19 CA CA3240991A patent/CA3240991A1/en active Pending
- 2023-01-19 CN CN202380017824.7A patent/CN118574619A/zh active Pending
- 2023-01-19 EP EP23702056.5A patent/EP4465989A1/en active Pending
- 2023-01-19 US US18/728,991 patent/US20250099535A1/en active Pending
- 2023-01-19 WO PCT/EP2023/051177 patent/WO2023139147A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN118574619A (zh) | 2024-08-30 |
| WO2023139147A1 (en) | 2023-07-27 |
| EP4465989A1 (en) | 2024-11-27 |
| JP2025502442A (ja) | 2025-01-24 |
| US20250099535A1 (en) | 2025-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lima et al. | In-depth characterization of antibacterial activity of melittin against Staphylococcus aureus and use in a model of non-surgical MRSA-infected skin wounds | |
| US8153166B2 (en) | Composition for prophylaxis or treatment of urinary system infection and method thereof | |
| Grüneberg et al. | The comparative in-vitro activity of ofloxacin | |
| EP3993796B1 (en) | Combination for the treatment of infections caused by mycoplasma genitalium | |
| US9839634B2 (en) | Antibacterial agents: combination of a rifamycin and a switch region inhibitor | |
| EP3946342A1 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| US20250099535A1 (en) | Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus | |
| CN111870601A (zh) | 一种6-二甲氨基喹啉芳香乙烯衍生物在制备抗耐药菌药物中的应用 | |
| Eur | Summary of Product Characteristics | |
| CN101543506A (zh) | 预防或治疗猪链球菌病的复方抗生素组合物 | |
| Dastidar et al. | Triflupromazine: a microbicide non-antibiotic compound | |
| KR102203849B1 (ko) | 동물용 복합 항생제 조성물 | |
| BRPI0918593B1 (pt) | composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas | |
| CN115778936A (zh) | 松萝酸协同增效多黏菌素在抗革兰氏阴性细菌感染中的应用 | |
| US20220184071A1 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| WO2013138748A1 (en) | Prevention of clostridium difficile infection in high risk patients | |
| Sushomasri et al. | Potential of dopamine hydrochloride as a novel antimicrobial agent | |
| WO2026077990A1 (en) | Novel use | |
| US20050020567A1 (en) | Method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent | |
| EP3294317B1 (en) | Enhanced antibiotic composition | |
| Shales | Surgical wound infection and antimicrobial prophylaxis | |
| Wagenlehner et al. | Urinary bactericidal activity of doripenem versus levofloxacin in patients with complicated urinary tract infections or pyelonephritis | |
| Richard | Cystitis in women treatment with levofloxacin preparations. Application of levofloxacin in urological practice | |
| Wada et al. | Studies of fluoroquinolone-resistant escherichia coli isolated from urinary tract infections between 1994 and 2006 in japan | |
| JP2001097864A (ja) | 呼吸管および尿路病原性細菌に対するフルオロキノリン化合物の使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241223 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241223 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251218 |